	US 11,739,156 B2
	Methods and compositions for overcoming immunosuppression
Amy Li, Cambridge, MA (US); Rebecca H. Herbst, Cambridge, MA (US); Aviv Regev, Cambridge, MA (US); Tyler Jacks, Cambridge, MA (US); and David Canner, Cambridge, MA (US)
Assigned to The Broad Institute, Inc. Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Jan. 6, 2020, as Appl. No. 16/735,187.
Claims priority of provisional application 62/788,952, filed on Jan. 6, 2019.
Prior Publication US 2020/0216551 A1, Jul. 9, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/24 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); C12N 9/22 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); C07K 16/244 (2013.01); C07K 16/30 (2013.01); C12N 9/22 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/732 (2013.01)]

8 Claims

1. A population of T cells obtained by a method comprising shifting T cell balance in a population of T_regcells comprising contacting ex vivo a population of CD103⁺ KLRG1⁺ (double-positive, DP) T_regcells with one or more agents capable of reducing or inhibiting or ablating ST2 and/or IL-33 signaling.